Background: The effectiveness of the 5 US Food and Drug Administration–approved
pharmacologic therapies for dementias in achieving clinically relevant improvements is …

An important aspect of brain cholinesterase function is related to enzymatic differences. The
brain of mammals contains two major forms of cholinesterases: acetylcholinesterase (AChE) …

At present, there may be over 210,000 people with Down syndrome (DS) over the age of 55
in the United States (US) who have significant needs for augmented services due to …

Background: Cholinesterase inhibitors (ChEIs) are the only drugs marketed for the treatment
of Alzheimer's disease. Despite numerous randomized controlled trials, the efficacy and …

Description: The American College of Physicians and American Academy of Family
Physicians developed this guideline to present the available evidence on current …

Similar to the state of the broader intellectual disabilities field, many gaps exist in the
research and treatment of mental health concerns in people with Down syndrome. This …

Down syndrome (DS) is the leading cause of genetically-defined intellectual disability and
congenital birth defects. Despite being one of the first genetic diseases identified, only …

Behavioural and psychological symptoms of dementia (BPSD) occur in 50–90% of
Alzheimer's disease (AD) patients. Imbalance of different neurotransmitters (acetylcholine …

Background Research based on retrospective reports by carers suggests that the
presentation of dementia in people with Down's syndrome may differ from that typical of …

Down syndrome (trisomy 21) is the most common cause of mental retardation in children
and leads to marked deficits in contextual learning and memory. In rodents, these tasks …